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TREATMENT OF HEMOPHILA WITH
HUMAN FACTOR X PRODUCED IN
MAMIMARY TISSUE OF TRANSGENIC
MAMMALS

Factor XIa and Factor VIIa? tissue factor are both calcium

dependent. However, the Factor VIIa/tissue factor pathway
requires tissue factor that is released from damaged endothe
lial cells. Activated human Factor IX thus exists as a disulfide

CROSS-REFERENCE TO RELATED PATENT
APPLICATIONS

This application is a continuation of U.S. patent applica
tion Ser. No. 10/062,447, now abandoned, filed on Feb. 5,
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2002, which is a division of application Ser. No. 09/367,087,
filed on Sep. 15, 1999, now Pat. No. 6,344,596, which claims
benefit of PCT/US98/02638, filed on Feb. 13, 1998, which
claims benefit of 60/037,145 filed on Feb. 14, 1997, all of

which are incorporated herein by reference in their entirety.
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BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to the production of natural
and modified forms of Factor IX. In particular, the invention
relates to a transgenic animal containing, stably incorporated
in its genomic DNA, an exogenous Factor IX gene that is
expressed specifically in mammary tissue. Such that Factor IX
is secreted into milk produced by the animal. In particular, the
invention relates to the production of human Factor IX in the
milk of a transgenic non-human mammal using a DNA mol
ecule that comprises a whey acidic protein promoter gene, 5'
regulatory sequences containing the promoter, human Factor
IX cDNA that lacks at least a portion of the complete or any
portion of or the complete the 3'-untranslated region of the
native human Factor IX gene, but contains the 5' and 3-un
translated region of the mouse whey acidic protein gene.
2. Background
Human Factor IX, or “Christmas factor, is encoded by a
single-copy gene residing on the X-chromosome at q27.1. For
a review of Factor IX gene structure and expression, see High
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et al., “Factor IX, in MOLECULAR BASIS OF THROM

BOSIS AND HEMOSTASIS, High (ed.), pages 215-237 (De
kker 1995); Kurachi et al., Thromb. Haemost 73:333 (1995).
The Factor IX gene is at least 34 kilobase (kb) pairs in size,
and it is composed of eight exons. The major transcription
start site of the Factor IX gene in human liver is located at

40

about nucleotide-176. The human Factor IX mRNA is com

posed of 205 bases for the 5' untranslated region, 1383 bases
for the prepro Factor IX, a stop codon and 1392 bases for the
3' untranslated region.
Factor IX is synthesized as a prepropolypetide chain com
posed of three domains: a signal peptide of 29 amino acids, a
propeptide of 17 amino acids, which is required for Y-car
boxylation of glutamic acid residues, and a mature Factor IX
protein of 415 amino acid residues. The Factor IX Zymogen
undergoes three types of post-translational modifications
before it is secreted into the blood: a vitamin K-dependent
conversion of glutamic acid residues to carboxyglutamic
acids, addition of hydrocarbon chains, and B-hydroxylation
of an aspartic acid. Mature Factor IX protein contains 12
Y-carboxylated glutamic acid (Gla) residues. Due to the
requirement of vitamin K by Y-carboxylase, Factor IX is one
of several vitamin K-dependent blood coagulation factors.
The activation of Factor IX is achieved by a two-step
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molecule. Bajaj et al., “Human factor IX and factor IXa, in
METHODS IN ENZYMOLOGY (1993). The first cleavage

is made at the Arg-Ala'site by either Factor XIa or Factor
made at Arg'-Val. The activation pathways involving

hr/ml of active rFIX were detected in CHO cells even after

coexpression of the propeptide cleaving enzyme PACE, coex
pression of the carboxylase enzyme, and extensive gene
amplification with methotrexate in an attempt to increase
expression level and activity (Wasley etal. J. Biol. Chem. 268:
8458-84.65 (1993); Rehemtulla et al., Proc. Natl. Acad. Sci.
(USA), 90: 4611-4615 (1993)). Researchers concluded that
multiple limitations in the secretion of active rFIX exist in
mammalian cells (Rehemtulla et al., 1993) and that the prob
lem of gene transcription was secondary and indeed trivial
with respect to post-translational processing of biologically
active rFIX in mammaliancells. Thus, FIX mRNA splicing is
a species specific effect occurring in mice and perhaps sheep,
but not pigs. Although one might hypothesize that a FIX could
be expressed, one could not predict with any certainty
whether Such product would be a clinically acceptable, prac
tical, recombinant therapeutic FIX product for a given hemo
philiac indication.
Production of recombinant Factor IX in mammalian cell

removal of the activation peptide (Ala'-Arg') from the

VIIa?tissue factor. The second, and rate limiting cleavage is

linked heterodimer of the heavy chain and light chain. Forfull
biological activity, human Factor IX must also have the
propeptide removed and must be fully Y-carboxylated. Kura
chi et al., Blood Coagulation and Fibrinolysis 4:953 (1993).
Factor IX is the precursor of a serine protease required for
blood clotting by the intrinsic clotting pathway. Defects in
Factor IX synthesis result in hemophilia B (or Christmas
disease), an X-linked disorder that occurs in about one in
30,000 males. Patients with hemophilia B are treated with
Factor IX obtained from pooled plasma from normal indi
viduals. Martinowitz et al., Acta Haematol 94(Suppl. 1):35
(1995). Such Factor IX preparations, however, may be pyro
genic and may be contaminated with pathogenic agents or
viruses. Accordingly, it would be advantageous to develop a
means to prepare purified Factor IX that did not require
extraction from human plasma.
In the past, therapeutic proteins have been produced in E.
coli. However, limitations in secretion and post-translational
modification which occur in all living cells has rendered
recombinant protein production a highly species, tissue and
cell specific phenomena. In an example of recombinant FIX
expression in mammalian cells, the populations of recombi
nant FIX produced in baby hamster kidney cells are not the
same protein products as FIX produced in Chinese hamster
ovary cells (Busby et al., Nature 316:684-686 (1985); Kauf
man et al., J. Biol. Chem. 261: 9622-9628 (1986)). These
proteins have profound differences in Y-carboxylation and
propeptide removal and these differences have been estab
lished as being very important in determining biological
activity. Most importantly, only less than about 40 milliunits/
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culture (HepG2, mouse fibroblast, mouse hepatoma, rat
hepatoma, BHK, CHO cells) repeatedly has been shown to be
recalcitrant and cell-system specific with respect to intracel
lular restrictions on secretion and proteolytic processing,
post-translational modification, expression levels, biological
activity, downstream recovery from production media, and
substantiation of circulation half-life (Busby et al., (1985); de
la Salle et al. Nature 316: 268-270 (1985); Anson et al.,
Nature 315: 684-686 (1985); Rehemtulla et al., 1993: Wasley,
et al., (1993); Kaufman et al., (1986); Jallatet al., EMBO.J.9:
3295-3301 (1990)). Importantly, the aforementioned works
concluded that nontrivial improvements in these combined
criteria are needed if a practical prophylactic FIX therapeutic
product is to be made available from any recombinant mam
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malian cell production source. For example, attempts to
increase the specific activity of rEIX produced by CHO cells
by rectifying problems with under-carboxylation by co-ex
pression of the vitamin K-dependent carboxylase enzyme
resulted in no improvement in Y-carboxylation or biological
activity (Rehemtulla et al., (1993), implying that multiple rate
limitations in this post-translational modification exist.
Similar difficulties in the production of significant amounts
of biologically active rFIX in the mammary epithelial cells of
transgenic animals also has been documented in the literature.
Although WO-A-90/05188 and WO-A-91-08216 predict that
production of rEIX should be possible in their production
systems, no data are presented in WO-A-91-08216, and only
very low levels of secreted rEIX (25 ng/ml) with no biological
activity were reported in transgenic sheep in WO-A90/05188
and in related publications, (Clark et al., Bio/Technology 7:
487-4992 (1989)). Higher expression levels have recently
been reported in the milk of sheep (5 ug/ml), but again, the
product had no biological activity (Colman, IBC Third Inter
national Symposium on Exploiting Transgenic Technology
for Commercial Development, San Diego, Calif. (1995)).
This demonstrates that the polypeptides produced in WO-A90/05188, Clark et al. (1989), and Colman (1995) were a
different species than native human FIX with dissimilar bio
logical activity to human FIX, and could never be used for
therapeutic purposes. Work by Clarket al. (1992) stated that
problems in synthesis of rPIX in the mammary gland of
transgenic mice was the result of aberrant splicing of the rEIX
mRNA in the 3' untranslated region. Correction of the aber
rant splicing in transgenic mice has been demonstrated (Yull
et al. Proc. Natl. Acad. Sci. USA 92: 10899-10903 (1995);
Clark, et al. (1989), WO95/30000)), resulting in higher
expression levels (up to 61 ug/ml) with about 40% biological
active material. However, this aberrant splicing phenomenon
appears to be species- and tissue-specific in the mouse mam
mary gland; other reports with the 3'UTR sequences in CHO
cell lines and in the liver of transgenic mice specifically show
no evidence of aberrant splicing (Kaufman et al., (1986);
Jallat et al., (1990)). In addition, no evidence was reported for
aberrant mRNA splicing of FIX transcripts with 3' UTR
sequences in a human hepatoma cell line (de la Salle et al.,
(1985)), amouse fibroblast cell line (de la Salleet al., (1985)),
a rathepatoma cell line (Anson et al., 1985)), or a BHK cell
line (Busby et al., (1985)). No data are presented to justify the
prediction that the altered transgene of WO95/30000 will
necessarily improve the Secretion and biological activity of
rFIX in the milk of transgenic livestock or any other cell line.
Therefore the claims presented in WO95/30000 are purely
speculative and are limited to the mammary gland of trans
genic mice.
The stability of the rFIX product in the milk of transgenic
livestock during upstream and downstream processing is a
critical issue for the production of a practical therapeutic.
Data presented in Clark et al. (1989) showed that Clark's
method of downstream recovery of what little rFIX was in the
milk of their transgenic sheep was not reproducible: in one of
the preparations, a significant amount of rPIX was proteolyti
cally activated. The infusion of activated FIX (FIXa) into a
patient is fatal (Kingdon et al., Thrombosis, Diathes. Haem
orrh. (Stuttg.) 33: 617 (1975)). FIX can be activated by F.XI
and/or FVIIa/Tissue factor complex in the presence of cal
cium and phospholipids (Kurachi et al., Blood Coagulation
and Fibrinolysis 4: 953-974 (1993)). Milk is a medium con
taining calcium and phospholipid surfaces. In addition, there
is extensively conserved homology between mammalian
blood coagulation factors, especially between porcine FXI
and human FXI (Mashiko and Takahashi, Biol. Chem. Hoppe
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Seyler 375: 481-484 (1994)). Detectable levels of porcine
FVII(a) and FXI(a) in the milk of nontransgenic pigs, and
elevated levels of FVII(a) and FXI(a) in the milk of a pig with
mastitic milk have been measured. Thus, one could predict
that the recovery of a useful unactivated rFIX produced in the
milk of transgenic livestock will be very sensitive to the
health of the mammary gland (i.e., no subclinical or clinical
mastitis), to the milking procedure (i.e., no tissue damage), to
pretreatment of the milk immediately after collection, to stor
age of the milk before processing, and to the purification and
formulation process itself. One would also predict that the
undesirable in vivo activation of rPIX also can be minimized

15

by the coexpression of inhibitors to FVIIa/TF such as the
Tissue Factor Pathway Inhibitor (TFPI) protein, also called
LACI, or the hybrid protein FX-LACI which is also a known
inhibitor to FVIIa/TF. Although specific inhibitors of FXIa
have not been identified, a similar approach can be made for
neutralizing FXIa activation by coexpression of analogues of
polypeptide substrates of FXIa similar to those that are com
mercially available for amidolytic assays. Yet another strat
egy may be to overexpress rFIX at very high levels (> 1 g/1
milk) such that the FIX activating enzyme is extremely lim
iting. Otherwise, steps must be taken immediately after milk
collection to minimize activation. These include, but are not

25

30

35

40

45

50

55

60

65

limited to, chelation of calcium (e.g., addition of EDTA),
phospholipid removal, adjustment of pH, storage in ultra-low
freezers, controlled thawing procedures, addition of protease
inhibitors, and purification procedures that maintain minimal
activation conduciveness. If activated rEIX still persists in the
purified product, removal can be facilitated by lectin chroma
tography(N-linked carbohydrate moieties exist only in the
activation peptide), immunoaffinity chromatography using a
Mab directed to the activation peptide, or by metal ion
induced precipitation techniques that can select for the dif
ferences in molecular stability of unactivated vs. activated
FIX. Because of these inherent difficulties in production of
active FIX at sufficiently high levels in mammalian cells and
transgenic livestock, gene therapy has been cited as perhaps a
more practical way of achieving a prophylactic therapeutic
rather than recombinant technology (Kurachi et al., (1993);
Kay et al., Proc. Natl. Acad. Sci. USA 91: 2353-2357 (1994));
Fallaux et al., Thromb-Haemost. 74: 266-73 (1995)). This is
certainly a profound reality because it specifically teaches a
product suitable for FIX prophylaxis has not yet been found
using recombinant production in mammalian cells, even
those that have been shown to express active FIX, albeitat low
levels. The best recombinant FIX cell production system
made from CHO cells is produced at low secretion levels
(Rehemtulla et al., (1993)) and is in fact not suitable for
prophylaxis. Furthermore, the data have shown that the
homologous plasma proteins. FIX and protein Call have very
different, cell-specific restrictions on post-translational pro
cessing, proteolytic processing, and secretion which preclude
on a protein-specific basis the predictability of high expres
sion levels, biological activity, downstream recovery from
production media, and predictable circulation half-life (Grin
nell et al., “Native and Modified recombinant human protein
C: function, secretion, and postranslational modifications. In
Protein C and Related Anticoagulants, eds. D. F. Bruley and
Drohan 29-63, Gulf Publishing Co., Houston, Tex. (1990);
Yan et al., Trends in Biochem. Sci. (1989); Busby et al.,
(1985)).
Therefore, a need still exists for a means to obtain signifi
cant amounts of purified Factor IX from a source other than
human plasma. A need also exists for a practical means for
producing in mammalian cells rPIX, which is Suitable as a
treatment for hemophilia B.

US 7,419,948 B2
5
SUMMARY OF THE INVENTION

Accordingly, it is an object of the present invention to
provide a method for producing a transgenic animal that
secretes biologically human active Factor IX into its milk.
It is a further object of this invention to provide a transgenic
animal that produces at least 100 ug of human Factor IX per

5

milliliter of milk.

These and other objects are achieved, in accordance with
one embodiment of the present invention by the provision of
a transgenic non-human mammal containing an exogenous
DNA molecule stably integrated in its genome.
A non-human transgenic mammal containing an exog
enous DNA molecule stably integrated in its genome,
wherein said exogenous DNA molecule comprises:
(a) 5' regulatory sequences of a mammary gland-specific
gene including a promoter;
(b) a Factor IX-encoding DNA sequence that encodes a
signal sequence, a Factor IX pro-sequence and a Factor
IX sequence in a 5' to 3" direction, wherein said signal
sequence is effective in directing the secretion of said
Factor IX into the milk of said transgenic mammal and
wherein said Factor IX sequence lacks at least a portion
of the complete or the complete 5'-untranslated and
3'-untranslated regions of the Factor IX gene.; and
(c) 3' regulatory sequences from a mammary gland-spe
cific gene or 3' regulatory sequences active in a mam
mary gland;
wherein said 5' and said 3' regulatory sequences are opera
tively linked to said Factor IX-encoding DNA sequence.
Mammary gland-specific promoters that are useful in the
present invention are selected from the group consisting of
short whey acidic protein (WAP) promoter, long WAP pro
moter, short C.-casein promoter, short B-casein promoter,
short kappa-casein promoter, long C-casein promoter, long
B-casein promoter, long kappa-asein promoter, C.-lactalbu
min promoter and B-lactoglobulin promoter.
Non-human transgenic mammals which are contemplated
by the present invention are selected from the group consist
ing of mice, rats, rabbits, pigs, sheep, goats and cows.
It is a further object to provide a process for producing
Factor IX by providing a non-human transgenic mammal
having integrated into its genome an exogenous DNA mol
ecule, wherein said exogenous DNA molecule comprises:
(a) providing a non-human transgenic mammal having
integrated into its genome an exogenous DNA molecule,
wherein said exogenous DNA molecule comprises: (1)
5' regulatory sequences of a mammary gland-specific
gene including a promoter; (2) a Factor IX-encoding
DNA sequence that encodes a signal sequence, a Factor
IX pro-sequence and a Factor IX sequence in a 5' to 3'
direction, wherein said signal sequence is effective in
directing the secretion of said Factor IX into the milk of
said transgenic mammal and wherein said Factor IX
sequence lacks at least a portion of the complete or the
complete 5'-untranslated and 3'-untranslated regions of
the Factor IX gene.; and (3)3'regulatory sequences from
a mammary gland-specific gene or 3' regulatory
sequences active in a mammary gland; wherein said 5'
and said 3' regulatory sequences are operatively linked
to said Factor IX-encoding DNA sequence;
(b) allowing said DNA sequences encoding said Factor IX
to be expressed and said Factor IX to be secreted into the
milk of said transgenic mammal;
(c) collecting said milk from said mammal; and
(d) isolating said Factor IX from said milk.
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It is a further object to provide a method of treating hemo
philia B using the Factor IX produced by the transgenic
mammal, described above. Treating involves administration
of the Factor IX of the invention and a pharmaceutically
acceptable carrier to a hemophilia B patient.
It is a further object of the invention to provide an in vitro
culture of mammary gland cells that produce Factor IX.
Another object of the invention is to provide a method of
treating hemophilia B by implanting Such Factor IX mam
mary gland cells into a patient.
BRIEF DESCRIPTION OF THE DRAWINGS

15
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FIGS. 1A-1D schematically depict the construction of a
chimeric Factor IX construct. Specifically, FIG. 1A shows the
construction of pWAP4. FIG. 1B shows the production of
pUCFIX. FIG. 1C shows the introduction of human FIX
cDNA into pWAP4. FIG. 1D shows the production of
pUCWAPFIX. FIX cDNA was modified by PCR in order to
introduce KpnI sites on the 3' and 5' ends. Using FIX cDNA
as a template, PCR primers humFIX5'KpnI and
humFIX3'KpnI, as shown in Table 1, below, were used to
produce FIX cloNA with KpnI sites on both ends. Modified
cDNA may be easily into a “cassette vector' for constructing
a chimeric gene.
FIG. 2 shows the detection of recombinant Factor IX in

transgenic pig milk using western blot analysis.
FIGS. 3A-3C show the production of the puCWAP6"cas
sette vector.” Specifically, FIG. 3A shows the production of
pUCNotI. FIG.3B shows the production of of puCWAP5 and
the production of a fragment that contains the puCNotIvec
tor sequence flanked by mWAP3'UTR. FIG. 3C shows the
production of puCWAP6.
FIG. 4 shows the production of plasmid puCWAP6FIX.
35

DETAILED DESCRIPTION

1. Overview
40

45

50

As discussed above, a method for producing significant
quantities of Factor IX in transgenic animals has been elusive.
Yull et al., Proc. Nat'l Acad. Sci. USA 92: 10899 (1995),
showed that correction of a cryptic RNA splice site increases
the amount of Factor IX synthesized by transgenic animals. In
these studies, one transgenic mouse line produced about 27
ug of biologically active Factor IX per milliliter of milk,
although, Factor IX levels of individual mice of the line
varied. Yull et al. speculated that the variation was probably
due to epigenetic instability.
In contrast, the studies presented herein show that trans
genic pigs can synthesize and secrete high levels (100-200
ug/ml milk) of biologically active recombinant human Factor
IX in milk. Based on reduced and nonreduced SDS PAGE, the

55

60

majority of the recombinant human Factor IX population
appears to be a single chain polypeptide having a post-trans
lationally modified structure similar to human Factor IX. The
recombinant human Factor IX secreted into pig milk is bio
logically active and is able to initiate clotting in Factor IX
deficient human plasma. This is the first reported production
of high levels of fully active, sufficiently Y-carboxylated,
recombinant human Factor IX in the milk of transgenic live
stock.

65

2. Methods for Producing Transgenic Animals
Notwithstanding past failures to express recombinant
human Factor IX with suitably high activity in several differ
ent expression systems, the present invention provides meth
ods for obtaining recombinant Factor IX characterized by a
high percentage of active protein from the milk of transgenic

US 7,419,948 B2
animals. As used herein, the term “animal’ denotes all mam
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catenated in vivo as additional flanking sequences to the

malian animals except humans. It also includes an individual
animal in all stages of development, including embryonic and
fetal stages. A “transgenic' animal is any animal with cells
that contain genetic information received, directly or indi
rectly, by deliberate genetic manipulation at the subcellular
level, such as by microinjection or infection with recombi

target Factor IX cDNA construct.
Methods for obtaining transgenic animals are well-known.
See, for example, Hogan et al., MANIPULATING THE
MOUSE EMBRYO, (Cold Spring Harbor Press 1986);
Krimpenfort et al., Bio/Technology 9:88 (1991); Pallinter et
al., Cell 41:343 (1985); Kraemeret al., GENETIC MANIPU

nant virus.

LATION OF THE EARLY MAMMALIAN EMBRYO,

7

The genetic information to be introduced into the animal is
preferably foreign to the species of animal to which the recipi
ent belongs (i.e., "heterologous'), but the information may
also be foreign only to the particular individual recipient, or
genetic information already possessed by the recipient. In the
last case, the introduced gene may be differently expressed
than is the naturally occurring, or “native.” gene.
The language 'germ cell line transgenic animal” refers to a
transgenic animal in which foreign DNA has been incorpo
rated into a germ line cell, therefore conferring the ability to
transfer the information to offspring. If such offspring, in fact,
possess some or all of that information, then they, too, are
transgenic animals.
The transgenic animals of this invention are other than
human, including, but not limited to farm animals (pigs,
goats, sheep, cows, horses, rabbits and the like), rodents (such
as mice), and domestic pets (for example, cats and dogs).
Livestock animals such as pigs, sheep, goats and cows, are
particularly preferred.
Preferably, a transgenic animal of the present invention is
produced by introducing into single cell embryos appropriate
polynucleotides that encode human Factor IX, or fragments
or modified products thereof, in a manner Such that these
polynucleotides are stably integrated into the DNA of germ
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line cells of the mature animal, and are inherited in normal
Mendelian fashion.

In accordance with the invention, DNA molecules can be

introduced into embryos by a variety of means to produce
transgenic animals. For instance, totipotent or pluripotent
stem cells can be transformed by microinjection, calcium
phosphate mediated precipitation, liposome fusion, retroviral
infection or by other means. The transformed cells can then be
introduced into embryos and incorporated therein to form
transgenic animals. In a preferred method, developing
embryos can be infected with retroviral vectors and trans
genic animals can be formed from the infected embryos. In
the most preferred method, however, the DNA molecules of
the invention are injected into embryos, preferably at the
single-cell stage, which are allowed to develop into mature
transgenic animals. However, the present invention is not
limited to this preferred method but other methods of making
transgenic animals can be used as described, for example, in
Transgenic Animal Generation and Use by L. M. Houdebine,
Harwood Academic Press, 1997. Transgenic animals also can
be generated using methods of nuclear transfer or cloning
using embryonic or adult cell lines as described for example
in Campbell et al., Nature 380: 64-66 (1996) and Wilmut et
al., Nature 385: 810-813 (1997). Further a technique utilizing
cytoplasmic injection of DNA can be used as described in
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3. Construction of Chimeric Genes

Suitable Factor IX-encoding DNA used for producing
transgenic animals can be obtained using human liver tissue
as a source for cloning the human Factor IX gene. The DNA
coding for Factor IX can be fused, in proper reading frame,
with appropriate regulatory signals, as described in greater
detail below, to produce a chimeric construct which is then
amplified, for example, by propagation in a bacterial vector,
according to conventional practice.
The amplified construct is thereafter excised from the vec
tor and purified for use in microinjection. The purification is
preferably accomplished by means of high performance liq
uid chromatography (HPLC), which removes contamination
of the bacterial vector and from polysaccharides typically
present when other techniques, such as conventional agarose
electroelution, are used: The preferred HPLC method entails
Sorbing the construct onto an anion-exchange HPLC Support
and selectively eluting the construct from the support, pref
erably with an aqueous sodium chloride Solution, thereby to
eliminate contamination from the vector. Elution also may be
effected by other means, such as a pH gradient.
Alternatively, the excised construct can be purified by
ultracentrifugation through an aqueous Sucrose or sodium
chloride gradient, gel electroelution followed by agarose
treatment and ethanol precipitation, or low pressure chroma
tography.
Since it is preferable that the construct have the minimum
amount of impurities, more than one cycle of HPLC or other
purification is advantageous. In particular, the use of HPLC
purified DNA for microinjection, as described above, allows
for remarkably high transformation frequencies, on the order
of 20% or more, for example, in mice and pigs.
DNA constructs useful in the present invention provide a
DNA sequence encoding Factor IX, preferably human Factor
IX, operably linked to all the cis-acting signals necessary for
mammary tissue specific expression of Factor IX, post-trans
lational modification of Factor IX, secretion of Factor IX into
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U.S. Pat. No. 5,523,222.

Factor IX-producing transgenic animals can be obtained
by introducing a chimeric construct comprising Factor IX
encoding sequences. An alternative method of producing
transgenic animals is to introduce a Factor IX chimeric con
struct with a second construct that may provide higher expres
sion more frequently than that observed with the use of Factor
IX constructs alone. As described herein, such doubly-trans
genic, or “bigenic animals have native WAP genomic
sequences that are injected as separate constructs to be con

(Cold Spring Harbor Laboratory Press 1985); Hammer et al.,
Nature 315:680 (1985); Wagner et al., U.S. Pat. No. 5,175,
385; Krimpenfort et al., U.S. Pat. No. 5,175,384, Janne et al.,
Ann. Med. 24:273 (1992), Brem et al., Chim. Oggi. 11:21
(1993), Clarket al. U.S. Pat. No. 5,476,995, hereby incorpo
rated by reference.
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milk, and full biological activity of Factor IX. Although the
present invention preferably entails the use of DNA con
structs that produce the desired or native human Factor IX per
se, the desired protein also may be produced as a fusion
protein containing another protein. For example, the desired
recombinant protein of this invention may be produced as part
of a larger recombinant protein in order to stabilize the
desired protein or to make its purification from milkfaster and
easier. The fusion partners then are separated chemically or
enzymatically, and the desired protein isolated.
Methods for obtaining human-Factor IX-encoding DNA
molecules and nucleotide sequences of human Factor IX gene
and cDNA are provided, for example, by Kurachi et al., Proc.
Nat’l Acad. Sci. USA 79:6461 (1982), Choo et al., Nature
299: 178 (1982), Anson et al., EMBO J. 3:1053 (1984),
Brownlee et al., international publication No. WO 84/00560,
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Yull et al., Proc. Nat'l Acad. Sci. USA 92: 10899 (1995),
Clark, international publication No. WO95/30000, and
Meulien, U.S. Pat. No. 5,521,070 (1996). Human Factor IX
probes also can be obtained from the AmericanType Culture
Collection, Rockville, Md. (e.g., ATCC Nos. 61385, 79588,
79602, or 79610).
Alternatively, Factor IX-encoding DNA molecules may be
obtained by synthesizing the genes with mutually priming
long oligonucleotides. See, for example, Ausubel et al., Supra,
at pages 8.2.8 to 8.2.13: Wosnicket al., Gene 60:115 (1987).
Moreover, the polymerase chain reaction can be used to Syn
thesize DNA fragments as large as 1.8 kilobases in length.
Bambot et al., PCR Methods and Applications 2:266 (1993).
Suitable Factor IX-encoding DNA molecules include
genomic or complementary DNA molecules that encode
naturally occurring Factor IX. In a preferred embodiment,
DNA molecules encoding human Factor IX are employed,
including cDNA and genomic DNA molecules. However, the
present invention discloses that a cDNA based construct as
described herein can be successfully used for the expression
of human Factor IX at commercially useful levels. Particu
larly, a cDNA based construct containing 5' regulatory
sequences of a mammary gland specific gene including a
promoter, a Factor IX-encoding DNA sequence as described
herein, and 3' regulatory sequences from a mammary gland
specific gene or 3' regulatory sequences active in a mammary
gland is preferred. Factor IX-encoding DNA molecules from
other species may also be used. Such as the Factor IX encoded
by rats, pigs, sheep, cows and chimpanzees.
It also will be appreciated that the Factor IX cDNA frag
ment described herein can be modified using recombinant
DNA techniques to obtain functionally equivalent molecules.
For example, 3' or 5" portions of the Factor IX gene can be
added, or completely deleted, or a few bases at either end may
be removed. Introns can be removed or added, or portions of
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one or more introns can be deleted. Additional nucleotide

sequences can be inserted into them. The sequences of the
introns can be altered. Exons can be modified in accordance
with the discussion of modified Factor IX molecules set forth

below. Most modified forms of the preferred Factor IX cDNA
fragment will not be significantly changed in their ability in
transgenic animals to engender the production of milk-born
Factor IX. In one embodiment, the Factor IX encoding por
tion of the gene lacks the complete 5'-untranslated and 3'-un
translated regions of the native Factor DX gene. Thus, these
Substantially similar fragments will be equivalent in the
invention to the particularly disclosed Factor IX cDNA frag
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ment.

A 5'-untranslated region that is not the 5'-untranslated
region of the Factor IX gene can be included in the present
DNA Factor IX constructs, particularly the 5'-untranslated
region of the mouse WAP gene. Likewise a 3'-untranslated
region that is not the 3'-untranslated region of the Factor IX
gene, particularly the 3'-untranslated region of the mouse
WAP gene.
Further, the Factor IX-encoding DNA molecule can also
comprise a 5'-untranslated region located 5' from the signal
sequence DNA, and a 3'-untranslated region located 3' from
the Factor IX coding sequence.
Additional useful modifications of Factor IX include those

that alter post-translational modifications, size or active site,
or that fuse this protein orportions thereof to another protein.
Such modifications can be introduced into the protein by
techniques well known in this art, Such as, by Synthesizing
modified genes by ligation of overlapping oligonucleotide or
introducing mutations into the cloned genes by, for example,
oligonucleotide-mediated mutagenesis. See, generally,
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Ausubel et al. (eds.), CURRENT PROTOCOLS IN
MOLECULAR BIOLOGY, pages 8.0.3-8.5.9 (1990);
McPherson (ed.), DIRECTED MUTAGENESIS: A PRAC
TICAL APPROACH, IRL Press (1991).
The examples described herein demonstrate that a trans
genic animal can be produced that synthesizes a Sufficiently
Y-carboxylated, biologically active Factor IX in mammary
tissue. Accordingly, the basic methods of the present appli
cation can be used to obtain transgenic animals that produce
other vitamin K-dependent blood coagulation factors, such as
Factor II, Factor VII, Factor X, or the anticoagulation protein,
Protein S. DNA molecules encoding these proteins can be
obtained by standard methods. See, for example, Pollak et al.,
J. Biol. Chem. 271: 1738 (1996), which describes the charac
terization of the Factor VII gene, which is located on chro
mosome 13 just 2.8 kilobase pairs 5' to the Factor X gene.
The cis-acting regulatory regions useful in the invention
include the promoter that drives expression of the Factor IX
gene. Promoters particularly useful in the invention are
“active' in mammary tissue in that the promoters are more
active in mammary tissue than in other tissues under physi
ological conditions where milk is synthesized. Most pre
ferred are promoters that are both specific to and efficient in
mammary tissue. By “efficient' it is meant that the promoters
are strong promoters in mammary tissue that can Support the
synthesis of large amounts of protein for secretion into milk.
Among Such promoters, highly preferred are the short and
long whey acidic protein (WAP), short and long C, 3 and
kappa casein, C.-lactalbumin and B-lactoglobulin (“BLG')
promoters.

Promoters may be selected on the basis of the protein
compositions of milk from various species. For example, the
WAP and BLG promoters are particularly useful with trans
genic rodents, pigs and sheep. The rodent WAP short and long
promoters have been used to express the rat WAP gene, the
human tissue-type plasminogen activator gene and the CD4
gene, while the sheep BLG promoter has been used to express
the sheep BLG gene, the human alpha-1-antitrypsin gene and
the human Factor IX gene. See, for example, Paleyanda et al.,
1991, above, and Clark et al., TIBTECH 5: 20 (1987). Pre
ferred promoters include the rodent casein and WAP promot
ers, and the casein, C.-lactalbumin and BLG promoters from
porcine, bovine, equine and ovine (pigs, sheep, goats, cows,
horses), rabbits, rodents and domestic pets (dogs and cats).
The genes for these promoters have been isolated and their
nucleotide sequences have been published. See, for example,
Clark et al. (1987), above, and Henninghausen, Protein
Expression and Purification 41: 3 (1990).
A useful promoter may be isolated by carrying out conven
tional restriction endonuclease and Subcloning steps. A
mouse WAP promoter, isolated as a 2.6 kb EcoRI-KpnIfrag
ment immediately 5' to the WAP signal sequence, is preferred,
although the “long WAP promoter (the 5' 4:2 kb Sau3A
KpnI promoter of the mouse WAP gene, or a fragment
thereof) is also suitable for carrying out this invention. The
publication of Paleyanda et al., Transgenic Research 3:335
(1994), for example, provides examples of a suitable short
mouse WAP promoter (2.5 kb mWAP promoter) and a long
mouse WAP promoter (“4.1 kb mWAP promoter”). Pages
336-339 of the Paleyanda publication are incorporated by
reference. Also see, for example, Gordon et al., Bio/Technol
ogy 5: 1183 (1987); McKnight et al., “The Whey Acidic
Protein, in GENES, ONCOGENES, AND HORMONES:
ADVANCES IN CELLULAR AND MOLECULAR BIOL
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OGY OF BREAST CANCER, Dickson et al. (eds.), pages
399-412 (Kluwer Academic Publishers 1991). Additional
regulatory sequences direct secretion of proteins into milk
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and/or other body fluids of the transgenic animal. In this
regard, both homologous and heterologous regulatory
sequences are useful in the invention. Generally, regulatory
sequences known to direct the Secretion of milk proteins. Such
as either signal peptides from milk or the nascent target
polypeptide, can be used, although signal sequences can also
be used in accordance with this invention that direct the

secretion of expressed proteins into other body fluids, par
ticularly-blood and urine. Examples of Such sequences
include the signal peptides of secreted coagulation factors
including signal peptides of Factor IX, protein C, and tissue
type plasminogen activator.
Among the useful sequences that regulate transcription, in
addition to the promoters discussed above, are enhancers,
splice signals, transcription termination signals, polyadeny
lation sites, buffering sequences, RNA processing sequences
and other sequences which regulate the expression of trans
genes. Particularly useful in this regard are those sequences
that increase the efficiency of the transcription of the genes for
Factor IX in the mammary gland or other cells of the trans
genic animals listed above. Preferred are transcription regu
latory sequences for proteins highly expressed in the mam
mary gland cells.
Preferably, the expression system or construct of this
invention also includes a 3' untranslated region downstream
of the DNA sequence encoding the desired recombinant pro
tein, or the 3' untranslated region of the milk protein gene or
the milk protein gene with its 3' untranslated region, any of
which can be used for regulation. This region can increase
expression of the transgene. This region apparently stabilizes
the RNA transcript of the expression system and thus
increases the yield of the desired protein. Among the 3'
untranslated regions useful in this regard are sequences that
provide a polyA signal.
For expression of Factor IX, it is preferred that the 3'
untranslated region is not obtained from the native human
Factor IX gene. Suitable heterologous 3'-untranslated
sequences can be derived, for example, from the SV40 small
tantigen, the casein 3' untranslated region, or other 3' untrans
lated sequences well known in this art. Preferably, the 3'
untranslated region is derived from a milk-specific protein,
such as the WAP protein. The stabilizing effect of this
region's poly A transcript is important in stabilizing the
mRNA of the expression sequence. Ribosome binding sites
are also importantin increasing the efficiency of expression of
Factor IX. Likewise, sequences that regulate the post-trans
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Obtaining milk from a transgenic animal according to the
present invention is accomplished by conventional means.
See, for example, McBurney et al., J. Lab. Clin. Med. 64:485
(1964); Velander et al., Proc Nat'l Acad. Sci. USA 89:12003
(1992). Factor IX, or fragments thereof, can be isolated and
purified from milk or urine by conventional means without
deleteriously affecting activity. A preferred method of isola
tion from milk consists of a combination of anion exchange
and immunochromatography, cryoprecipitations, Zinc ion
induced precipitation of either whole milk or milk whey
(defatted milk) proteins. See, for example, Bringe et al., J.
Dairy Res. 56:543 (1989).
Milk is known to contain a number of proteases that have
the potential to degrade foreign proteins. These include an
alkaline protease with tryptic and chymotryptic activities, a
serine protease, a chymotrypsin-like enzyme, an aminopep
tidase and an acid protease. Clarket al. (1987) above. It may
be desirable, therefore, to protect newly secreted Factor IX, or
fragments thereof, against proteolytic degradation. Such pre
cautions include rapid processing of the milk after collection
and addition to the milk of well known inhibitors of proteoly
sis, such as are listed in SIGMA CHEMICAL CO. CATA
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lational modification of Factor IX are useful in the invention.

In a particularly preferred embodiment, the transgenes of
the invention generally consist of WAP milk protein regula
tory sequences upstream and downstream flanking the Factor
IX cloNA?signal peptide sequences. A native 5'-WAP regula
tory sequence ending in an accessible restriction site imme
diately before/at the ATG codon may be ligated to the restric
tion sites that occur at the ATG of translatable sequences with
no linker sequences derived from the chains of human Factor
IX. Each of the combined 5'-regulatory and Factor IX trans
latable sequences ending in a particular restriction site may
then be ligated to a corresponding restriction site which
occurs at the beginning of the 3'-untranslated region of WAP
and adjoining WAP 3'-flanking region. This construction
motif enables native 5'-regulatory and 3'-untranslated region
of the milk protein genes to be immediately juxtaposed with
out intervening sequences. Particular restriction sites at the
ends of all constructs may be selected in order to facilitate
concatenation of constructs into a single domain within the
animal genome.

12
Thus, in accordance with the present invention a DNA
molecule that encodes Factor IX is operably linked to cis
acting regulatory sequences which allow for efficient expres
sion of Factor IX in milk. The resulting chimeric DNA is
introduced into a mammalian embryo, where it integrates into
the embryonic genome and becomes part of the heritable
genetic endowment of all the cells, including the germ line
cells, of the adult which develops from the embryo. The
Factor IX which is expressed in the mammary tissue and
secreted into the milk of a transgenic mammal obtained in this
manner displays a Surprisingly high percentage of active pro
tein, as measured by enzymatic and coagulation-inhibition
assays which are conventionally employed to detect Factor IX
activity, Such as ELISAS, chromogenic activity assays and
coagulation inhibition assays.
4. Isolation of Factor IX from the Milk of Transgenic
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LOG (1993 edition) at page 850.
Thus, in one embodiment, the transgenic mammal of the
present invention produces active human Factor IX. For
instance, in one embodiment wherein said mammal is a pig,
such pig secretes from about 100 to about 220 g of active
human Factor IX per milliliter milk. In another embodiment,
such pig secretes from abort 100 to about 185ug of active
human Factor IX per milliliter milk, from about 100 to about
170 ug of active human Factor IX per milliliter of milk, from
about 135 to about 220 g of active human Factor IX per
milliliter of milk or from about 145 to about 220 ug of active
human Factor IX per milliliter of milk, as set forth below.
Factor IX produced from the transgenic mammal accord
ing to the invention has a specific activity which is at least
about 5 to 200 percent greater than the specific activity of
human Factor IX isolated from human plasma, as determined
by an activated partial thromboplastin clotting time assay. In
another embodiment, the specific activity of Factor IX pro
duced by the transgenic mammal of the invention is at least
about 10 to 100 percent greater, at least about 15 to 50 percent
greater or at least about 15 to about 46 percent greater than the
specific activity of human Factor IX isolated from human
plasma.
In another embodiment, the invention relates to an in vitro
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culture of mammary gland cells explanted from the trans
genic mammal of the invention. Such cells are explanted and
cultured in vitro, according to methods well known to the
skilled artisan. See e.g., U.S. Pat. No. 5,580,781. In another
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embodiment, Factor IX is isolated and purified from the in
vitro cell culture, according to methods well known to the
skilled artisan.
5. Treatment Methods

In another embodiment, the present invention relates to a
method of treating hemophilia Busing Factor IX produced by
the transgenic mammal of the invention. Specifically, treat
ment includes the prevention or amelioration of the Symp
toms of hemophilia B in hemophilia B patients. Symptoms of
hemophilia B include excessive bleeding upon injury, spon
taneous bleeding, especially into weight-bearing joints, soft
tissues and mucous membranes. Repeated bleeding into
joints results in hemarthroses, which causes painful crippling
arthropathy that necessitates joint replacement. Hematomas
in-Soft tissues may result in “pseudo” tumors composed of
necrotic coagulated blood. Such blood can obstruct, com
press orrupture into adjacent organs and can lead to infection.
Bleeding into gastrointestinal tract, central nervous system,
intracranium or airway/retroperitoneal space can lead to
death if not detected. This, treatment according to the present
invention includes the prevention or amelioration of bleeding
and the related side effects found in hemophilia B patients.
This method involves administering to a patient having hemo
philia B symptom, a hemophilia B symptom preventing or
ameliorating amount of Factor IX produced by the transgenic
mammal of the present invention. Administration may be
accomplished by any method known to the skilled artisan. For
instance, the treatment of the above described symptoms may
consist of intravenous replacement therapy with Factor IX
concentrates. Treatment of major bleeding episodes may be
by bolus injection of concentrate. However, as described
above, tissue damage may remain even after prompt detection
and treatment. Prophylactic treatment is recommended to
prevent pain and debilitation. Upon injection, 50% of Factor
IX, according to the invention, is immediately bound to vas
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cular endothelial cells and/or diffuses into the extravascular

space. The remaining 50% has a half life in circulation of
approximately 24 hours. These infusion kinetics result in the
need for injections about once to twice per week to maintain
minimal therapeutic levels in the plasma.
Another embodiment of the invention relates to pharma
ceutical compositions comprising the Factor IX of the present
invention. Such pharmaceutical composition preferably is
Factor IX produced by the above described transgenic animal
and a pharmaceutically acceptable carrier. For instance. Such
pharmaceutical composition may be a stable liquid formula
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This skilled artisan would know of other suitable formula

tions for the Factor IX of the present invention. See, for
instance, AlphaNine by Therapeutic Corporation, Los Ange

hemorrhages, it may be desirable to raise Factor IX levels to
30 to 50% and infusions may be required daily. Again, those
of skill in the art would know how to adjust the amount and
frequency of dosages of the Factor IX of the present invention
depending upon the patient and the clinical setting.
In yet another embodiment, the invention relates to a
method of treating hemophilia Busing Factor IX-producing
cells that are explanted from the transgenic mammal of the
present invention. Such mammary gland cells express Factor
IX in Vivo, thereby preventing or ameliorating the symptoms
of hemophilia B. This method is accomplished by using
known techniques for gene therapy. See e.g., Debs, R. Proc.
Natl Acad. Sci. (USA) 89: 11277-11281 (1992), Legendre et
al., Pharmaceutical Res. 9:1235-42 (1992). In one embodi
ment, Factor IX-producing cells removed from the transgenic
mammal according to the invention are cultured in an in vitro
culture system prior to transplantation into a human. Such
culture systems are well known to the skilled artisan. See e.g.
U.S. Pat. No. 5,580,781. The cells are treated and then trans
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planted into the patient in a manner so as to avoid rejection by
the recipient. Such methods are known to the skilled artisan.
See, for instance, U.S. Pat. No. 5,573.934, which teaches a

tion of the Factor IX of the invention that can be administered

by continuous infusion to provide a constant circulating level
of the coagulation factor.
The Factor IX produced by the transgenic animal of the
present invention may be concentrated and sold in lyophilized
form, according to methods well known to the skilled artisan.
For instance, the Factor IX of the present invention which has
been lyophilized may be reconstituted with sterile water for
injection (WH) and delivered in a composition of 0.01 moles/
liter histidine, pH 7.05; 0.066 moles/liter sodium chloride:
3% mannitol. In another embodiment, lyophilized Factor IX
is reconstituted in sterile WFI and delivered in a composition
that includes: 0.04 units heparin/unit FIX: 1 milligram dex
trose/unit Factor IX. To avoid repeated invasive treatments as
is found with the current therapies for prophylaxis, stabilities
of at least 30 days at 37° C. and at least 365 days at 4°C. are
preferred. The present invention provides significant stability
over that of these preparations reconstituted.
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les, Calif., and Bebulin V. H. by Immuno, Vienna, Austria. Of
course, any formulations according to the present invention
are highly purified and free of viruses, prions, blood-group
antibodies, immune complexes and phospholipids.
Dosages or amounts that prevent or ameliorate the symp
toms of hemophilia B are necessarily dictated by the clinical
picture and severity of the disease. Because there is so much
variability between patients and their clinical conditions,
monitoring of coagulation function is essential in during any
therapy using the Factor IX of the invention. As a rule, on
initial treatment, one unit of Factor IX per kg body weight
gives a mean rise in Factor IX activity of about 0.5-1%, on
continuation therapy, the mean rise is about 1-1.5% Examples
of dosages for long term prophylaxis of symptoms of hemo
philia B are about 18-30 IU/kg (1x weekly) or about 9-15
IU/kg (2x weekly). Dosages also will vary depending upon
the purpose of the treatment. For instance, where a hemo
philia B patient has had surgery, it may be desirable to raise
Factor IX levels in such patients by 30 to 50% following the
week of surgery. For dental extractions, the Factor IX levels
may need to be raised to 50% immediately prior to the sur
gery. Mild to moderate hemorrhages may be treated with a
single administration of the Factor IX of the invention to raise
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method of encapsulating biological material for use in vivo.
Other techniques known to the skilled artisan involve placing
the biological material in a chamber of an immunoisolation
apparatus and for enhancing the vascular Support for the
implanted material using immunomodulatory agents. See,
U.S. Pat. No. 5,569,462.
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The present invention, thus generally described, will be
understood more readily by reference to the following
examples, which are provided by way of illustration and are
not intended to be limiting of the present invention.
EXAMPLE 1.
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Preparation of a Human Factor IX Expression Vector
for Production of Transgenic Pigs
Generally, the entire murine WAP gene including 2.5 kb of
5' untranslated sequence and 3' untranslated regions was
cloned by standard methods. See Campbell et al., Nucleic
Acids Res. 12:8685 (1984). A cDNA fragment encoding
human Factor IX was obtained and the 3' untranslated region
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was deleted. Using standard methods, an expression vector
was constructed that contained a mouse WAP promoter, iso
lated as a 2.6 kb EcoRI-KpnI fragment immediately 5' to the
WAP signal sequence, the human Factor IX cDNA sequence
lacking a 3' untranslated region, and a 1.6 kb fragment of the
3' untranslated region of the WAP gene. A second expression
vector contained a 7.2 kb mouse WAP gene (EcoRI-EcoRI)
fragment. Expression vectors were amplified by bacterial
transformation and purified from bacterial cultures using
standard methods. Routine recombinant DNA techniques can
be found, for example, in Sambrook et al., MOLECULAR
CLONING, A LABORATORY MANUAL, Vol. 1-3 (Cold
Spring Harbor Press 1989).
More specifically, a chimeric Factor IX construct was pre
pared, as follows:
1. Preparation of a Chimeric Factor IX Construct Produc
tion of pWAP4 “Cassette Vector
Regulatory 5' and 3’ flanking sequences of the mouse WAP
gene were used for mammary specific expression. Specifi
cally, a cassette vector containing a mouse WAP promoter,
defined as a 2.6. kb EcoRI-KpnI fragment immediately 5' to
the WAP signal sequence and a 1.5 kb fragment of the 3'
untranslated region of the WAP gene was prepared. These
regulatory sequences do not include coding and intragenic
untranslated sequences (introns) of the WAP gene.
The vector designated pWAP4 was derived from
pWAPPC3 (C. Russell, dissertation “Improvement of
Expression of Recombinant Human Protein C in the Milk of
Transgenic Mammal Using a Novel Transgenic Construct.”
Virginia Technology Institute, Blacksburg, Va. (December
1993)) and was developed as follows: Using WAPPC3 as a
template, PCR primers WAP3'S2 (which contains a 5'KpnI
site and is homologous to endogenous WAP right after the
stop signal) and WAP3'A1, as shown in Table 1, below, were
used to produce a segment with KpnI and BamHI sites on
either end. This segment was digested with KpnI/BamHI and
ligated with the vector containing the fragment from
KpnI\BamHI digested pWAPPC3. The ligation mixture was
used to transform E. coli DH5C. cells by electroportation with
resultant colonies grown on LB amplicillin plates. Picked
colonies were grown up in TB ampicillin broth, plasmids
isolated and cut with Kp41, BamHI or both and subjected to
gel electrophoresis. Sequencing was performed using
WAP3'A1 primer and judged as being correct. See FIG. 1A.
Production of Modified (Kpn I) FIX cDNA
The FIX cDNA (containing Kpn I sites located immedi
ately before the start sequence and after the stop sequence)
was generated as a PCR fragment. Fragment production pro
tocol is as follows: 100 ul total volume containing 200 uM
dNTPs, 0.5 M of each primer (humFIX5'KpnI and
humFIX3'KpnI, as shown in Table 1), 2.5 units Pfu poly
merase and 30 ng of plasmidtemplate (pMCDSFIX obtained
from Prof. Darryl Stafford, Department of Biology, Univer
sity of North Carolina, Chapel Hill, N.C., USA), reaction
mixture was subjected to 30 cycles of denaturation at 95°C.
for 20 sec, annealing at 50° C. for 1 min and elongation at 75°
C. for 5 min 45 sec. After cycling, the reaction mixture was
subjected to blunting with T4 DNA polymerase for 10 min,
EDTA concentration brought up to 25 mM, heated to 65° C.
for 15 min, and extracted with Phenol: Chloroform (1:1),
precipitated with equal volumes of 95% ethanol, aspirated,
and Suspended in H2O.
Ligation, Transformation and Sequencing
As is shown in FIG. 1B, the plasmid designated puCFIX
containing the modified (Kpn I ends) FIX cDNA was pro
duced by digestion of both puC18 and the modified cDNA
with Kpn I (per manufacturers instructions, Stratagene, La
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Jolla, Calif.) purification of digestion products by CHCl:
Phenol (1:1) extraction, precipitation with equal volumes of
95% ethanol, aspiration and Suspension in H2O. Ligation of
plasmid and cDNA was per manufacturers instructions (Strat
agene) using 125 ng of Kpn I digested puC18 and 125 ng of
Kpn I digested modified cDNA. E. coli JM109 was trans
formed by electroportation using ligation mixture and plated
on LB amplicillin plates. Selected colonies were grown up in
TB ampicillin broth. Plasmid preparations from these colo
nies were analyzed by restriction enzyme digestion (Kpn I)
and gel electrophoresis. The entire sense strand of the cDNA
was sequenced and found to be correct as compared with
FIXA sequences located in Genebank.
Introduction of FIX cDNA into pWAP4 “Cassette Vec
torto Produce pWAPFIX
As shown in FIG. 1C, both pWAP4 and puCFIX were
digested with Kpn I in separate reactions, Subjected to gel
electrophoresis and the appropriate plasmid fragments
removed from the gel and ligated. E. coli JM109 was trans
formed by electroportation using ligation mixture and plated
on LB amplicillin plates. Selected colonies were grown up in
TB ampicillin broth. Plasmid preparations from these colo
nies were analyzed by restriction enzyme digestion (Kpn I)
then gel electrophoresis. Clones positive for the insert were
subjected to PCR analysis using primers FIXS1 and
WAP3A1 to determine the correct orientation of the insert.
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Production of puCWAPFIX
As shown in FIG. 1D, the insert containing WAP promoter,
cDNA and 3'WAP UTR was released from pWAPFIX by
EcoR I digestion, Subjected to gel electrophoresis, removed
from the gel and purified. This fragment was ligated with Kpn
Idigested puC18 and the reaction mixture used to transform
E. coli JM109 by electroportation. After electroportation,
cells were plated on LB ampicillin plates with picked colonies
grown in TBampicillin broth. Plasmids from picked colonies
were purified and subjected to EcoRI enzyme digestion and
electrophoresis. After insert confirmation, large scale purifi
cation was undertaken, according to methods well known to
the skilled artisan.

2. Preparation of Factor IX-Encoding DNA for Microin
jection
Chimeric constructs containing either the 7.2 kb mouse
WAP gene, or containing the WAP promoter, human Factor
IX gene and 3' WAP sequence were excised from puCWAP
FIX by EcoRI restriction digest and purified for microinjec
tion using low melting point agarose electrophoresis. The
DNA: agarose band was cut from the gel slab. The agarose
band was then treated with agarase to degrade and remove
agarose contamination.
After digestion, the solution containing the cDNA was
brought to 10 mM Mg2+, 20 mM EDTA and 0.1% SDS and
then extracted with phenol/chloroform. DNA was precipi
tated from the aqueous layer with 2.5 volumes of ethanol in
the presence of 0.3 M sodium acetate ate -20 degrees centi
grade overnight. After centrifugation, the pellet was washed
with 70% ethanol, dried, and each of the constructs was

60

65

resuspended and dissolved in Brinsters microinjection buffer
to a concentration of 1.4 or 7 g/ml (for mice), 14 ug/ml (for
pigs).
According to another protocol, extracted DNA was puri
fied by HPLC, as follows. After cleaving a chimeric gene
from its vector, the solution was brought to 10 mM magne
sium, 20 mM EDTA and 0.1% SDS and then extracted with

phenol/chloroform. DNA was precipitated from the aqueous
layer with 2.5 volumes of ethanol in the presence of 0.3 M
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sodium acetate at -20°C. overnight. After centrifugation, the
pellet was washed with 70% ethanol, dried, and resuspended
in sterile distilled water.

The digested DNA was precipitated with isopropanol and
then dissolved in TE buffer at 0.3 g/ml. Fragments were 5
purified by HPLC using a Waters GEN FAX PAC HPLC
column. The column was run isocratically using a buffer
consisting of 25 mM Tris-HCl (pH 7.5), 1 mM sodium EDTA,
and 0.63 MNaCl. About 15ug of digested DNA was loaded
on the column at a time. DNA samples from all of the chro- 10
matographic runs were then pooled, reprecipitated, and run
through the column a second time.
DNA concentrations were determined by agarose gel elec
trophoresis by staining with ethidium bromide and compar
ing the fluorescent intensity of an aliquot of the DNA with the 15
intensity of standards. Samples were then adjusted to 10
ug/ml and stored at -20°C., prior to microinjection.
EXAMPLE 2
2O

Production of Transgenic Pigs that Express the
Human Factor IX Gene

18
The vector designated puCWAP6 was derived from
genetic elements from the following plasmids as starting
material: puC18, pWAP4 and p227.6, which were provided
by the American Red Cross. The development of puCWAP6
is as follows: The puC18 vector was cut with the enzymes
EcoRI and HindIII to remove the multiple cloning site of the
vector, blunted with exonuclease and ligated with NotI link
ers. The linearized plasmid was then cut with Not and
ligated. Ligation mixture was used to transform E. coli DH5C.
cells on LB amplicillin plates, picked colonies were grown in
TBampicillin broth, plasmids were isolated and cut with NotI
then Subjected to gel electrophoresis. Plasmid was judged to
be correct and designated as puCNotI (See FIG. 3A). The
vector pWAP4 was cut with EcoRI and the fragment contain
ing the WAP 52.6 kbp and 3' genetic elements were separated
by gel electrophoresis and purified. The ends of the fragment
were modified by blunting with exonuclease and NotI linkers
were ligated on. The fragment was cut with NotI and ligated
into the NotI restriction site of puCNotI then used to trans
form E. coli DH5C. cells on ampicillin plates picked colonies
were grown in TB amplicillin broth. Isolated plasmid was
verified to be correct by Not digestion with the plasmid being
designated puCWAP5. The puC WAP5 plasmid was sub
jected to KpnI digestion and a partial Not digestion produc
ing a fragment that contained the puCNot vector sequence
flanked by the mWAP 3'UTR (See FIG. 3B). This fragment
was ligated with the 4.1 kb 5’ WAP promoter produced from
digestion of p227.6 with NotI, Kipni and HindIII. The ligation

Pig embryos were recovered from the oviduct, and were
placed into a 1.5 ml microfuge tube containing approximately
0.5 ml embryo transfer media (Beltsville Embryo Culture
Medium). Embryos were centrifuged for 12 minutes at
16,000xg RCF (13.450 RPM) in a microcentrifuge (Hermle,
model Z231). The embryos were then removed from the
microfuge tube with a drawn and polished Pasteur pipette and
placed into a 35 mm petri dish for examination. If the cyto
plasm was still opaque with lipid such that pronuclei were not
visible, the embryos were centrifuged again for 15 minutes.
Embryos were then placed into a microdrop of media (ap
proximately 100 ul) in the center of the lid of a 100 mm petri
dish, and silicone oil was used to cover the microdrop and fill
the lid to prevent media from evaporating. The petri dish lid
containing the embryos was set onto an inverted microscope
(Carl Zeiss) equipped with both a heated stage and Hoffman
Modulation Contrast optics (200x final magnification). A
finely drawn (Kopf Vertical Pipette Puller, model 720) and
polished (Narishige microforge, model MF-35) micropipette
was used to stabilize the embryos while about 1-2 picoliters of
HPLC-purified DNA solution containing approximately 200
500 copies of a mixture of the two chimeric constructs was
delivered into the male pronucleus with another finely drawn
micropipette. Embryos Surviving the microinjection process
as judged by morphological observation were loaded into a
polypropylene tube (2 mm ID) for transfer into the recipient

30 were grown on LB amplicillin plates picked colonies were
grown in TBampicillin broth, plasmids isolated were cut with
Not I, and Notl/KpnI and judged to be correct. The plasmid
was then designated puCWAP6 (See FIG. 3C).
Production of puCWAP6FIX
35 As shown in FIG.4, the plasmid puCWAP6FIX was pro
duced by digestion of puCWAPFIX with KpnI and isolating
the FIX clNA by gel electrophoresis. This fragment was
inserted into the KpnI site of puCWAP6 after Kipni digestion
and both fragments were then Subjected to ligation. The liga
40 tion mixture was then used to transform E. coli JM109 cells
that were then plated on LB amplicillin plates. Picked colonies
were grown in TB amplicillin broth and plasmids were iso
lated. Isolated plasmids were digested with NsiI to verify

pig.

50

25

mixture was then used to transform E. coli JM109 cells that

orientation of the cDNA insert. Plasmids that contained the

45 insert in the correct orientation were designated
pUCWAP6FIX. After insert confirmation, large scale purifi
cation was undertaken, according to methods well known in
the art. DNA was prepared for microinjection as described
above.
EXAMPLE 4

EXAMPLE 3

Production of Transgenic Mice that Express the
Production of puCWAP6 “Cassette Vector” and
Plasmid puCWAP6FIX Production of puCWAP6

Human Factor IX Gene

55

Transgenic mice were produced essentially as described by
Hogan et al., Manipulating the Mouse Embryo, Cold Spring
Generally, the entire murine WAP gene was cloned by Harbor Press, (1986), which is hereby incorporated by refer
standard methods, as described above in Example 1, and ence. That is, glass needles for micro-injection were prepared
regulatory 5' and 3’ flanking sequences of the mouse WAP 60 using a micropipet puller and microforge. Injections were
gene were used for mammary specific expression. Specifi performed using a Nikon microscope having Hoffman Modu
cally, a cassette vector containing a mouse WAP promoter, lation Contrast optics, with Narashigi micromanipulators and
defined as a 4.1 kb NotI-KpnI fragment immediately 5' to the a pico-injector driven by N2 (Narashigi).
WAP signal sequence and a 1.6 kb fragment of the 3' untrans
Fertilized mouse embryos were surgically removed from
lated region of the WAP gene was prepared. These regulatory 65 oviducts of superovulated female CD-1 mice and placed into
sequences do not include coding and intragenic untranslated M2 medium. Cumulus cells were removed from the embryos
with hyaluronidase at 300 g/ml. The embryos were then
sequences (introns) of the WAP gene.
“Cassette Vector'
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rinsed in new M2 medium, and transferred into M15 medium

EXAMPLE 6

for storage at 37 degrees centigrade prior to injection.
Stock solutions containing about 1.4 ug/ml of the above
described DNA were prepared and microinjected into the
pronuclei of 1 cell mouse embryos. In addition, Stock solu
tions containing about 7 g/ml total DNA were prepared and
microinjected into the pronuclei of mouse embryos.
After injecting the DNA solution into the male pronucleus,
embryos were implanted into avertin-anesthesized CD-1
recipient females made pseudo-pregnant by mating with
vasectomized males. About 25-30 microinjected mouse
embryos per recipient were transferred into pseudopregnant
females. Embryos were allowed to come to term and the
newborn mice were analyzed for the presence of the trans
gene by PCR using the primers FIXS1 and FIXA1 described

Analysis of DNA Derived from Tissue
To determine whether test animals carried the recombinant
5

10

tation.
15

in Table 1, below.
EXAMPLE 5

Preparation of DNA from Transgenic Animals
DNA can be prepared from tissue of a transgenic animal of
any species by the method exemplified below for mice. Mar
mur., J. Mol. Biol. 3: 208 (1961), incorporated herein by

25

reference.

A 5 mm piece of mouse tail was removed from young,
potentially transgenic mice at weaning (3 weeks) age, and
frozen in liquid nitrogen. To the frozen tissue was added 840
ul of Lysing Solution (8 mM EDTA-0.8% 2-mercaptoetha
nol-80 g/ml Proteinase K-1 M sodium chlorate in 40 mM
TRIS buffer) pH 8.0 and 120 mM. NaCl, and the mixture
incubated at 50 degrees centigrade. The mixture was then
extracted with 250 ul of phenol/chloroform-fisoamyl alcohol
(25:24:1) for 10-15 seconds, then centrifuged for 10 minutes.
The supernatant fluid (about 830 ul) was removed to a fresh
tube, and a DNA clot produced by vortexing the solution with
0.6 vols. ofisopropanol. The mother liquor was decanted, and

30

for 10 minutes.

The DNA clot was dissolved in 250 ul of the TE buffer (10
mM Tris. HCl, pH 7.0-1 mM EDTA, and the solution treated
with 10 ul of RNase (1 mg/ml RNase A and 4,0000 units/ml
RNAse T1) for 1 hour at 37 degrees centigrade. This mixture
was shaken with 50 ul of a 24:1 (v/v) solution of chloroform
isoamyl alcohol for 5-10 seconds, centrifuged, and the Super

Oligonucleotide pairs were used to prime polymerase
chain reactions that detected the presence of the WAP gene or
the Factor IX gene in the transgenic animals. See Table 1,
below. Reactions were performed using an annealing tem
perature of 58°C., a denaturation temperature of 94°C., and
an extension temperature of 72° C., using 100 ng of oligo
primers and 50 ng of (genomic) template DNA per reaction,
and cycling through the temperatures 40 times using an auto
matic temperature cycler (M.J. Research). PCR reactions
were analyzed by running 20% of the reaction products on
agarose gels and identifying fragment sizes by comparison
with marker DNA fragments.
Two founder transgenic pigs (one male and one female)
contained a 2.6 kb mouse WAP promoter-Factor IX cDNA
1.6 kb WAP gene 3'-end construct that had been coinjected
with the 7.2 kb mouse WAP gene (EcoRI-EcoRI) fragment.
As shown in Table 2, the male, 57-7, did not transmit the
transgene. In contrast, founder 58-1 huas produced one
female offspring having the Factor IX cDNA transgene.
Founder 58-1 has produced six additional offspring, three
females and three males, from her second litter. The three

35

females were not transgenic. Two of the males from the
second litter tested positive for the Factor IX transgene.
TABLE 1.

Primer Sequences
40

humFIX5' (SEQ ID NO: 1)
humFIX3 ' (SEQ ID NO: 2)

Structures.

5'gtcavgg tacc\ttaagtgagct

KpnI
45

FIXS1

(SEQ ID NO : 3)

5'ggata acat cactcaaag cac

WAP3 "A1 (SEQ ID NO : 4)

5' tag cagoagattgaaagcattatg

FIXA1

5 "gtgaactttgtagatc

(SEQ ID NO: 5)

50

TABLE 2

natant fluid transferred to a fresh tube.

The recovered Supernatant fluid above was mixed sequen
tially with 25 ul of 3M sodium acetate and 0.5 ml of 95%
ethanol. The Supernatant fluid above was mixed sequentially
with 25ul of 3M sodium acetate and 0.5 ml of 95% ethanol.
The supernatant fluid was decanted from the precipitated
DNA, and the precipitate washed with 80% ethanol. The
purified DNA was isolated by centrifugation, air dried, then
dissolved in 150 ul of TE.
Essentially the same technique was used to prepare DNA
from pigs, and the same or similar techniques can be used to
prepare DNA from other animals. Such DNA can be analyzed
to determine whether transgenic animals carried recombinant

5'gcta\gg tacc\atgcagogcg

KpnI

the DNA clot rinsed twice with 80% ethanol. The DNA clot

was isolated by 5 minutes or centrifugation, aspiration of the
Supernatant fluid, and air drying of the clot with a stream of air

constructs, tissue samples were removed from transgenic ani
mals and treated with proteinase K and SDS at 37° C. over
night. The mixture was then incubated with DNase-free
RNase at 37°C. for 1-2 hours. DNA was precipitated from the
mixture with sodium acetate and ethanol at -20°C. overnight,
collected by centrifugation, washed in 70% ethanol and dried.
The dried DNA pellet was used directly for polymerase chain
reaction (PCR). In some cases, the mixture was extracted
extensively with phenol/chloroform prior to ethanol precipi

Transgenic Pigs Containing Recombinant Human Factor IX DNA
55 Pig ID

57-7

Construct

Sex

WAPFIX

Male

Comments

Founder, PCR* positive for
WAP and FIX

S8-1

WAPFIX

Female

Founder, PCR positive for WAP
and FIX

60

63-1

WAPFIX

Female

G' from 58-1, positive for WAP
and FIX

63-2

WAPFIX

litterii10

WAP.FIX

to 58-1
65

Female

G from 58-1, positive for WAP
and FIX (dead)

3Female,

2 transgenic males

3Male

WAP: Whey acid protein; FIX: Factor IX:
*Detection of human Factor IX transgene carried out by the PCR method.
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IX (as determined by polyclonal ELISA) and human Factor
IX standard (American Red Cross), were loaded in each lane.
A total of 25ug of total protein from a pool of non-transgenic
(NTG) whey was loaded on the gels. After electrophoresis,
proteins were transferred overnight to PVDF membranes
(Bio Rad). The membranes were washed for 30 minutes in

EXAMPLE 7

Expression of Human Factor IX in the Milk of
Transgenic Pigs
Daily expression levels of recombinant human Factor IX in
the milk of transgenic pig 58-1 were determined as follows.
Lactating sows were injected intramuscularly with 30-60 IU
of oxytocin (Vedco Inc., St. Joseph, Mo.) to stimulate milk
let-down. Letdown occurred two to five minutes after injec
tion. Pigs were milked by hand during the course of this study.
Immediately after collection the milk was diluted 1:1 with
200 mM EDTA, pH 7.0 to solubilize the caseins and then
frozen. Small aliquots (about one milliliter) of the milk/
EDTA mixture were taken and centrifuged for approximately
30 minutes at 16000xg at 4°C. The fat layer was separated
from the diluted whey fraction, and the diluted whey fraction
was used for all further assays. In this study, all concentration
values reported for milk were obtained from diluted whey
samples that were multiplied by a factor of 1.9 to account for
dilution with EDTA and subsequent removal of milk fat.
Amounts of Factor IX in milk were measured by poly
clonal ELISA. Briefly, Immulon II microtiter plates (Fisher
Scientific, Pittsburgh) were coated overnight with 100 ul/well
of 1:1000 rabbit anti-human Factor IX (Dako) in 0.1 M
NaHCO, 0.1 MNaCl, pH 9.6 at 4°C. The wells were washed
with TBS-Tween (TBST, 25 mM Tris, 50 mM NaCl, 0.2%
Tween 20, pH 7.2), and then blocked for 30 minutes with
TBS/0.1% BSA at room temperature. Samples and human
Factor IX standard (a gift from the American Red Cross) in
the TBS-BSA dilution buffer were added in triplicate to the
wells (100 ul/well) and incubated at 37° C. for 30 minutes.

TBST, blocked with TBS/0.05% Tween 20/0.5% Casein
10

15

45-50 kDa.
25
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BSA, was then incubated in the wells for 30 minutes at 37°C.,

followed by anti-goat IgG/HRP (Sigma, St. Louis). Bound
chromophore was detected with OPD substrate (Abbott, Chi
cago) at 490 nm using an EL308 Bio-Tek Microplate reader.
As shown in Table 3, daily expression levels of 100-220
ug/ml milk were maintained throughout the 10 day lactation.

In yet another study, whole milk from transgenic pig 58-1
was diluted 1:1 with 200 mM EDTA, pH 7.0 to dissociate
casein micelles. Milk was skimmed offat by centrifugation at
4000xg for 30 min, at 2° C. 100 ugs of milk protein were
loaded per lane of a 4%/10% SDS-PAGE gel and resolved at
15 mA/hr for one hour and 30 mA/hr for 2 hours. Proteins

The wells were then washed and blocked for another 10

minutes at room temperature. Goat anti-human Factor IX
(American Diagnostica, Greenwich, Conn.), 1:1000 in TBS

(TBST-Casein). The membranes were developed with rabbit
anti-Factor IX (Dako) (1:1000 in TBST-Casein for 45 min
utes at 37° C.), followed by anti-rabbit IgG/HRP (Sigma)
(1:1000 in TBST-Casein for 45 minutes at 37° C.), and the
DAB metal enhanced staining (Pierce). Molecular weight
markers were purchased from Bio Rad.
Western analyses revealed the presence of three sub-popu
lations of recombinant human Factor IX: the major popula
tion migrated at a M, of about 60-65 kDa, which is a slightly
lower M, than human Factor IX, and minor sub-populations
migrated at about 40-45 kDa, and at about 25 kDa. Plasma
human Factor IX also possessed a subpopulation at about

were transferred onto nitrocellulose paper (Amersham), at 24
V/h, 40°C. and western blotted to detect rRIX in milk, using
an HRP-conjugated goatanti-FIXantibody (Affinity Biologi
cals) at 0.9 ug/ml concentration. The results of this study are
set forth in FIG. 2, wherein lanes 1-8 represent milk from day
3, 4, 5, 6, 7, 9, 10, 11 of lactation; lane 9, purified recombinant
FIX, 1.0 lug; and lane 10, human FIX purified from plasma,
0.5ug. The positions of broad range molecular weight mark
ers (BioRad) are indicated on the left.

40

EXAMPLE 9

Purification of Human Factor IX from Milk of

Transgenic Pigs

TABLE 3
Recombinant Factor IX Levels in Milk of

45

Transgenic Pig 58-1, First Lactation

Day of Lactation

rhFIX Level g/ml)

1

16O 26
145 - 20
1OO 25
13S 15
22O3O
17O 3S
185 SO

*Recombinant human Factor IX (rhFIX) levels were determined by ELISA

50

then eluted with 0.25 M NaCl in TBS. This fraction was
55

on daily samples of EDTA-diluted whey.

EXAMPLE 8
60

Western Analysis of Human Factor IX Produced by
Transgenic Pigs
Recombinant human Factor IX also was examined using
Western analysis. Daily samples of EDTA-diluted whey from
58-1 were electrophoresed on 8-16% SDS gels (Novex, San
Diego). Approximately 125 ng of recombinant human Factor

Recombinant human Factor IX was purified from a pool of
the first lactation from the milk of 58-1 using ion exchange
chromatography followed by metal-dependent immunoaffin
ity chromatography (MAb 1H5). In these studies, all columns
and buffers were kept at 4° C. A pool of daily EDTA-ex
panded whey samples was diluted to OD 280 nm of 5.0 with
TBS, pH 7.2, then loaded at 1 cm/min on DEAE FF
Sepharose. The column was washed with TBS, pH 7.2, and

65

diluted 1:1 with 40mMMgCl, in TBS to a final concentration
of 20 mM MgCl2 and loaded on a 1H5 MAb column. The
column was washed with TBS containing 20 mM MgCl2, and
the product was eluted with 20 mM citrate, 0.15 MNaCl, pH
6.8. The product was dialyzed overnight against 10 mMimi
dazole, pH 7.2.
The yields from the anion exchange and immunoaffinity
steps were quantitative, and no recombinant human Factor IX
was detected in the flow-through chromatographic fractions
by polyclonal ELISA. This two-step chromatographic proce
dure isolated the recombinant human Factor IX to about

80-90% purity.
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plasma which had a specific activity of 230 U/mg, and the
normal plasma reference pool activity of 250 U/mg.
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EXAMPLE 10

The Biological Activity of Purified Recombinant
TABLE 4

Human Factor IX

The biological activity of the purified recombinant human
Factor IX from 58-1 was measured using a one-stage acti
vated partial thromboplastin clotting time assay (APTT) clot
ting assay following a protocol given by the American Red
Cross Plasma Derivatives Laboratory (Procedure for Factor
IX Coagulation Assay, March 1992). Briefly, each well of a
plastic Coag-a-mate tray received 90 ul of Factor IX-deficient
plasma plus 10 ul of a Factor IX standard or sample, diluted
with Tris/saline/BSA. The tray was then placed on an auto
mated analyzer (APTT mode, 240 second activation). The run
was started, which automatically performed the addition of
100 ul of APTT reagent and 100 ul of 0.025 M CaCl. Data
obtained using a standard Factor IX preparation were fitted to
the equation y-ax+b where y-clotting time and X-Factor IX,

Specific Activity of Recombinant Human Factor
IX Purified from the Milk of a Transgenic Pig

10

tion.

As shown in Table 4, the immunopurified recombinant
human Factor IX had a specific activity of 337 U/mg, which
is comparable to the immunopurified human Factor IX from

Slope
Ratio

Equation

Activity
(%)

Specific
Activity

NPRP
FDX
rhEIX

O.O94
O.O86
O.127

1.O
0.92
1.35

y = 0.094x -3.7
y = 0.086x - 3.6
y = 0.127x - 3.4

100%
92%
13.5%.

250 U/mg
230 U/mg
337 U/mg

NPRP: normal plasma reference pool
rhFIX: Factor DX isolated from the transgenic pig

Although the foregoing refers to particular preferred
embodiments, it will be understood that the present invention
is not so limited. It will occur to those of ordinary skill in the
art that various modifications may be made to the disclosed
embodiments and that such modifications are intended to be

a sample. The Standards of normal plasma reference pool
(Sigma) and human Factor IX (American Red Cross Plasma
Derivatives Laboratory) were used in the assay. Duplicates of
58-1 recombinant human Factor IX, human Factor IX, and

Slope

hFIX: human Factor IX standard
15

which was then used to determine the amount of Factor IX in

normal plasma reference pool samples were run at each dilu

Sample
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within the scope of the present invention, which is defined by
the following claims.
All publications and patent applications mentioned in this
specification are indicative of the level of skill of those in the
art to which the invention pertains. All publications and patent
applications are herein incorporated by reference to the same
extent as if each individual publication or patent application
were specifically and individually indicated to be incorpo
rated by reference in its entirety.

SEQUENCE LISTING
<16 Oc NUMBER OF SEO ID NOS: 5
<210

SEQ ID NO 1

<211
LENGTH: 2O
&212> TYPE: DNA

<213> ORGANISM: Homo sapiens
<4 OO

SEQUENCE: 1

gctaggit acc atgcagcgc.g
<21 Oc SEO ID NO 2
<211 LENGTH: 21
TYPE: DNA

ORGANISM: Homo sapiens
<4 OO

SEQUENCE: 2

gtcaggt acc ttaagtgagc t

21

SEO ID NO 3
LENGTH: 21
TYPE: DNA

ORGANISM: Homo sapiens
<4 OO

SEQUENCE: 3

ggata acatc actcaaag.ca c
SEO ID NO 4
LENGTH: 24
TYPE: DNA

ORGANISM: Murine

<4 OO

SEQUENCE: 4

21
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26
- Continued

tagcagcaga ttgaaagc at tatg

24

SEO ID NO 5
LENGTH: 16
TYPE: DNA

ORGANISM: Homo sapiens
<4 OO

SEQUENCE: 5

gtgaactittg tagatc

What is claimed is:

1. A method of treating a patient having hemophilia B
comprising administering to said patient a hemophilia B
symptom preventing or ameliorating amount of a biologically
active human Factor IX produced by a transgenic pig that
secretes the biologically active human Factor IX into its milk,
and wherein said transgenic pig comprises stably integrated
into its genome an exogenous DNA molecule encoding said
biologically active human Factor IX; and a pharmaceutically
acceptable carrier.
2. The method of claim 1, wherein said biologically active
human Factor IX has a specific activity that is at least about
15-50% greater than the specific activity of human Factor IX
isolated from human plasma.
3. The method of claim 1, wherein said transgenic pig
secretes at least 100 ug of biologically active human Factor IX
per milliliter of milk.

16

15

human Factor IX.

25

30

35

5. The method of claim 1, wherein said administration of

human Factor IX that is administered comprises about 9-15
IU/kg administered twice a week.
12. The method of claim 1, wherein said administration of
said human Factor IX raises Factor IX levels to 50% in the
blood.

said human Factor IX raises Factor IX levels 20% or greater
in the blood.

6. A purified or isolated biologically active human Factor
IX produced in a transgenic pig which secretes said biologi
cally active human Factor IX into its milk, wherein said

7. The biologically active human Factor IX of claim 6,
wherein said biologically active human Factor IX comprises
a specific activity that is at least about 15-50% greater than the
specific activity of human Factor IX isolated from human
plasma.
8. The biologically active human Factor IX of claim 6,
wherein said transgenic pig secretes at least 100 ug of bio
logically active human Factor IX per milliliter of milk.
9. The biologically active human Factor IX of claim 6,
wherein said biologically active human Factor IX comprises
a sufficiently Y-carboxylated, biologically active Factor IX.
10. The biologically active human Factor IX of claim 6,
wherein said biologically active human Factor IX further
comprises a pharmaceutically acceptable carrier.
11. The method of claim 1, wherein said amount of said

4. The method of claim 1, wherein said amount of said

human Factor IX that is administered comprises about 18-30
IU/kg administered once a week.

transgenic pig comprises stably integrated into its genome an
exogenous DNA molecule encoding said biologically active

40

13. The method of claim 1, wherein said biologically active
human Factor IX is isolated or purified from said milk.
k

k

k

k

k
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